Samuel M Miller1, Lauren E Wilson2, Melissa A Greiner2, Jessica E Pritchard2, Tian Zhang3, Deborah R Kaye4, Harvey Jay Cohen5, Robert D Becher6, Linda L Maerz6, Michaela A Dinan7. 1. National Clinician Scholars Program, Yale University, USA; Department of Surgery, Yale University, USA. Electronic address: Samuel.miller@yale.edu. 2. Department of Population Health Sciences, Duke University, USA. 3. Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, USA. 4. Department of Surgery, Division of Urology, Duke University, USA. 5. Center for the Study of Aging and Human Development, Duke University, USA. 6. Department of Surgery, Yale University, USA. 7. Department of Epidemiology, Yale University, USA.
Abstract
BACKGROUND: Dementia and cancer are both more common in adults as they age. As new cancer treatments become more popular, it is important to consider how these treatments might affect older patients. This study evaluates metastatic renal cell carcinoma (mRCC) as a risk factor for older adults developing mild cognitive impairment or dementia (MCI/D) and the impact of mRCC-directed therapies on the development of MCI/D. METHODS: We identified patients diagnosed with mRCC in a Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset from 2007 to 2015 and matched them to non-cancer controls. Exclusion criteria included age < 65 years at mRCC diagnosis and diagnosis of MCI/D within the year preceding mRCC diagnosis. The main outcome was time to incident MCI/D within one year of mRCC diagnosis for cases or cohort entry for non-cancer controls. Cox proportional hazards models were used to measure associations between mRCC and incident MCI/D as well as associations of oral anticancer agent (OAA) use with MCI/D development within the mRCC group. RESULTS: Patients with mRCC (n = 2533) were matched to non-cancer controls (n = 7027). mRCC (hazard ratio [HR] 8.52, p < .001), being older (HR 1.05 per 1-year age increase, p < .001), and identifying as Black (HR 1.92, p = .047) were predictive of developing MCI/D. In addition, neither those initiating treatment with OAAs nor those who underwent nephrectomy were more likely to develop MCI/D. CONCLUSIONS: Patients with mRCC were more likely to develop MCI/D than those without mRCC. The medical and surgical therapies evaluated were not associated with increased incidence of MCI/D. The increased incidence of MCI/D in older adults with mRCC may be the result of the pathology itself or risk factors common to the two disease processes.
BACKGROUND: Dementia and cancer are both more common in adults as they age. As new cancer treatments become more popular, it is important to consider how these treatments might affect older patients. This study evaluates metastatic renal cell carcinoma (mRCC) as a risk factor for older adults developing mild cognitive impairment or dementia (MCI/D) and the impact of mRCC-directed therapies on the development of MCI/D. METHODS: We identified patients diagnosed with mRCC in a Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset from 2007 to 2015 and matched them to non-cancer controls. Exclusion criteria included age < 65 years at mRCC diagnosis and diagnosis of MCI/D within the year preceding mRCC diagnosis. The main outcome was time to incident MCI/D within one year of mRCC diagnosis for cases or cohort entry for non-cancer controls. Cox proportional hazards models were used to measure associations between mRCC and incident MCI/D as well as associations of oral anticancer agent (OAA) use with MCI/D development within the mRCC group. RESULTS: Patients with mRCC (n = 2533) were matched to non-cancer controls (n = 7027). mRCC (hazard ratio [HR] 8.52, p < .001), being older (HR 1.05 per 1-year age increase, p < .001), and identifying as Black (HR 1.92, p = .047) were predictive of developing MCI/D. In addition, neither those initiating treatment with OAAs nor those who underwent nephrectomy were more likely to develop MCI/D. CONCLUSIONS: Patients with mRCC were more likely to develop MCI/D than those without mRCC. The medical and surgical therapies evaluated were not associated with increased incidence of MCI/D. The increased incidence of MCI/D in older adults with mRCC may be the result of the pathology itself or risk factors common to the two disease processes.
Authors: Terri G Monk; B Craig Weldon; Cyndi W Garvan; Duane E Dede; Maria T van der Aa; Kenneth M Heilman; Joachim S Gravenstein Journal: Anesthesiology Date: 2008-01 Impact factor: 7.892
Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Mayra Tisminetzky; Jerry H Gurwitz; Dongjie Fan; Kristi Reynolds; David H Smith; David J Magid; Sue Hee Sung; Terrence E Murphy; Robert J Goldberg; Alan S Go Journal: J Am Geriatr Soc Date: 2018-09-24 Impact factor: 5.562
Authors: Mateo P Farina; Mark D Hayward; Jung Ki Kim; Eileen M Crimmins Journal: J Gerontol B Psychol Sci Soc Sci Date: 2020-08-13 Impact factor: 4.077
Authors: Jonathan D Clapp; George Luta; Brent J Small; Tim A Ahles; James C Root; Deena Graham; Arti Hurria; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Robert A Stern; Andrew J Saykin; Jeanne S Mandelblatt Journal: Arch Clin Neuropsychol Date: 2018-12-01 Impact factor: 2.813
Authors: Jessica E Pritchard; Lauren E Wilson; Samuel M Miller; Melissa A Greiner; Harvey Jay Cohen; Deborah R Kaye; Tian Zhang; Michaela A Dinan Journal: J Am Geriatr Soc Date: 2022-05-02 Impact factor: 7.538